Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
Standard
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. / Bokemeyer, Carsten; Bondarenko, I; Hartmann, J T; de Braud, F; Schuch, Gunter; Zubel, A; Celik, I; Schlichting, M; Koralewski, P.
in: ANN ONCOL, Jahrgang 22, Nr. 7, 7, 2011, S. 1535-1546.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.
AU - Bokemeyer, Carsten
AU - Bondarenko, I
AU - Hartmann, J T
AU - de Braud, F
AU - Schuch, Gunter
AU - Zubel, A
AU - Celik, I
AU - Schlichting, M
AU - Koralewski, P
PY - 2011
Y1 - 2011
N2 - The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).
AB - The randomized phase II OPUS (Oxaliplatin and Cetuximab in First-Line Treatment of Metastatic Colorectal Cancer) study showed that tumor KRAS mutation status was predictive for outcome in patients receiving cetuximab plus FOLFOX-4 (oxaliplatin/5-fluorouracil/folinic acid) as first-line therapy for metastatic colorectal cancer (mCRC).
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Treatment Outcome
KW - Survival Rate
KW - Follow-Up Studies
KW - Polymerase Chain Reaction
KW - DNA, Neoplasm/genetics
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Leucovorin/administration & dosage
KW - Antibodies, Monoclonal/administration & dosage
KW - Proto-Oncogene Proteins/genetics
KW - Tumor Markers, Biological/genetics
KW - ras Proteins/genetics
KW - Mutation/genetics
KW - Colorectal Neoplasms/drug therapy/genetics/pathology
KW - Fluorouracil/administration & dosage
KW - Liver Neoplasms/drug therapy/genetics/secondary
KW - Organoplatinum Compounds/administration & dosage
KW - Proto-Oncogene Proteins B-raf/genetics
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Aged, 80 and over
KW - Young Adult
KW - Treatment Outcome
KW - Survival Rate
KW - Follow-Up Studies
KW - Polymerase Chain Reaction
KW - DNA, Neoplasm/genetics
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Leucovorin/administration & dosage
KW - Antibodies, Monoclonal/administration & dosage
KW - Proto-Oncogene Proteins/genetics
KW - Tumor Markers, Biological/genetics
KW - ras Proteins/genetics
KW - Mutation/genetics
KW - Colorectal Neoplasms/drug therapy/genetics/pathology
KW - Fluorouracil/administration & dosage
KW - Liver Neoplasms/drug therapy/genetics/secondary
KW - Organoplatinum Compounds/administration & dosage
KW - Proto-Oncogene Proteins B-raf/genetics
M3 - SCORING: Journal article
VL - 22
SP - 1535
EP - 1546
JO - ANN ONCOL
JF - ANN ONCOL
SN - 0923-7534
IS - 7
M1 - 7
ER -